Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 843 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo equivalent Clear all

Conditions: HIV Infections, Neuropathic Pain, Cannabis
Interventions: Receipt of Coupon for Placebo Soft-Gel Capsule, Receipt of Coupon for High THC Soft-Gel Capsule, Receipt of Coupon for Equal THC and CBD Soft-Gel Capsule, Receipt of Coupon for High CBD Soft-Gel Capsule; Other
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Obesity
Interventions: Oral Alcohol challenge test Alcohol visit first, Oral Alcohol challenge test Placebo visit first, Intravenous Alcohol Challenge Test (Clamp), Intravenous Alcohol Self-administration Test; Other
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 21 Years to 64 Years · Female only
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Bronchopulmonary Dysplasia (BPD)
Interventions: Inositol lower volume, Inositol mid-level volume, Inositol high volume, Placebo low volume; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 12 Hours to 72 Hours
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 17
States / cities: Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more

Conditions: Chronic Kidney Disease, Metabolic Acidosis
Interventions: Sodium bicarbonate, Placebo; Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 19 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: The Bronx, New York • Cleveland, Ohio

Conditions: HIV Infections
Interventions: DNA-HIV-PT123 vaccine, NYVAC-HIV-PT1 vaccine, NYVAC-HIV-PT4 vaccine, Placebo for DNA-HIV-PT123 vaccine, Placebo for NYVAC-HIV-PT1 vaccine, Placebo for NYVAC-HIV-PT4 vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 143 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 7
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 4 more

Conditions: Delirium, Sleep
Interventions: Dexmedetomidine, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years and older
Enrollment: 522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gastroesophageal Reflux, Apnea, Bradycardia
Interventions: Erythromycin, Multi-channel intra-luminal impedance (MII) pH monitoring, Placebo (D5W); Drug · Device
Lead sponsor: University of Virginia; Other
Eligibility: 14 Days and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Metabolic Syndrome, Insulin Resistance, DNA Damage
Interventions: Blueberry Powder, Placebo; Dietary Supplement
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 30 Years to 60 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Oakland, California

Conditions: Asthma
Interventions: Beclomethasone dipropionate, Placebo, Albuterol/salbutamol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 1,113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 94
States / cities: Costa Mesa, California • Huntington Beach, California • Long Beach, California + 77 more

Conditions: Covid-19 Prevention
Interventions: Ad26.COV2.S, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 1,085 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 7
States / cities: San Diego, California • Melbourne, Florida • Peoria, Illinois + 4 more

Conditions: Traumatic Brain Injury
Interventions: Placebo, Sertraline; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 85 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neoplasms, Prostate
Interventions: dutasteride, placebo, bicalutamide; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 90 Years · Male only
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 47
States / cities: Homewood, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 43 more

Conditions: Generalized Anxiety Disorder, Separation Anxiety Disorder, Social Anxiety Disorder
Interventions: Attentional Bias Modification Treatment (ABMT) - Active, Attentional Bias Modification Treatment - Placebo, Cognitive Behavioral Group Therapy, Psychoeducational Control Intervention; Other · Behavioral
Lead sponsor: Hospital de Clinicas de Porto Alegre; Other
Eligibility: 7 Years to 11 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Systolic Heart Failure
Interventions: Probenecid 1 gr oral twice daily, Placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: HIV-1-infection
Interventions: SAR441236, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 23
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more

Conditions: Cocaine Use Disorder
Interventions: NS2359, placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Influenza
Interventions: Placebo, Trivalent Inactivated Influenza; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 21 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Ulcerative Colitis
Interventions: NX-13 250mg, NX-13 750mg, NX-13 Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 11
States / cities: Miami, Florida • Orlando, Florida • Tampa, Florida + 8 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: JNJ-53718678 250 mg, Placebo, JNJ-53718678 125 mg; Drug
Lead sponsor: Janssen Sciences Ireland UC; Industry
Eligibility: 13 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 9
States / cities: Los Angeles, California • Detroit, Michigan • Minneapolis, Minnesota + 6 more

Conditions: Covid19
Interventions: Fenofibrate, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Herpes Simplex Type II
Interventions: TDF, Placebo Vaginal Gel, Vaginal TFV Gel, Placebo Tablets; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Delirium
Interventions: Quetiapine, Placebo; Drug · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Up to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions: Fecal Microbiota Transplant (FMT), Placebo; Biological
Lead sponsor: Stacy A. Kahn; Other
Eligibility: 5 Years to 30 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Refractory Generalized Myasthenia Gravis
Interventions: Eculizumab, Placebo; Biological · Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 41
States / cities: Birmingham, Alabama • Fresno, California • Los Angeles, California + 35 more

Search by objective public record fields.

Pain Inflammation and Cannabis in HIV

Alcohol and Bariatric Surgery

Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)

Alkali Therapy in Chronic Kidney Disease

Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults

Investigation of Sleep in the Intensive Care Unit

Study of Erythromycin in GER-Associated Apnea of the Newborn

Effect of Blueberry Consumption on Metabolic Syndrome & DNA Damage

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma

A Study of Ad26.COV2.S in Adults (COVID-19)

Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury

Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy

Combination of Active or Placebo Attentional Bias Modification Treatment (ABMT) to Either Cognitive Behavioral Group Therapy (CBGT) or Psychoeducational Control Intervention (PCI) for Anxiety Disorders in Children

Repurposing Probenecid as a Positive Inotrope for the Treatment of Heart Failure

Pharmacokinetics and Safety of SAR441236

Trial Of NS2359 For The Treatment of Cocaine Dependence

Th1 Response to Influenza: Aging and Vaccine Efficacy

Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)

Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors - Effect of Fenofibrate

Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding

Quetiapine Treatment for Pediatric Delirium

Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis

Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)